7-Thia-bicyclo<2.2.1>heptan | 279-59-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫杂环戊烷
• 英文名称: 7-Thia-bicyclo<2.2.1>heptan
• 英文别名: 7-Thiabicyclo[2.2.1]heptane
• CAS: 279-59-4
• 化学式: C₆H₁₀S
• 分子量: 114.211
• InChiKey: YADULIHSBVCGOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  7-Thia-bicyclo<2.2.1>heptan 生成 7-Thia-bicyclo<2.2.1>heptan-7,7-dioxid
  参考文献：
  名称：

  Preparation and Physical Properties of Sulfur Compounds Related to Petroleum. IX. 7-Thiabicyclo[2.2.1]heptane and 6-Thiabicyclo[3.1.1]heptane

  摘要：

  DOI：

  10.1021/jo01101a024
• 作为产物：
  描述：

  硫代乙酸 、 alkaline earth salt of/the/ methylsulfuric acid 生成 7-Thia-bicyclo<2.2.1>heptan 、 6-thia-norpinane
  参考文献：
  名称：

  Preparation and Physical Properties of Sulfur Compounds Related to Petroleum. IX. 7-Thiabicyclo[2.2.1]heptane and 6-Thiabicyclo[3.1.1]heptane

  摘要：

  DOI：

  10.1021/jo01101a024

文献信息

• [EN] PROCESS FOR THE PREPARATION OF ORGANIC BROMIDES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE BROMURES ORGANIQUES
  申请人：TECHNION RES & DEV FOUNDATION

  公开号：WO2017060905A1

  公开（公告）日：2017-04-13

  The present invention provides a process for the preparation of organic bromides, by a radical bromodecarboxylation of carboxylic acids with a bromoisocyanurate.

  本发明提供了一种有机溴化物的制备方法，通过使用溴异氰酸酯对羧酸进行自由基溴脱羧化反应。
• [EN] 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS<br/>[FR] DERIVES CYCLOALKYLES 1,1-DISUBSTITUES UTILISES EN TANT QU'INHIBITEURS DU FACTEUR XA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003099276A1

  公开（公告）日：2003-12-04

  The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

  本申请描述了1,1-二取代环烷基化合物及其衍生物，或其药用可接受的盐形式，这些化合物对于Xa因子的抑制剂具有用处。
• 1,3,4-Oxadiazoline derivatives and drugs containing these derivatives as active ingredient
  申请人：——

  公开号：US20030166574A1

  公开（公告）日：2003-09-04

  A 1,3,4-oxadiazoline derivative of formula (I) 1 , wherein W is oxygen, sulfer; R is hydrogen, alkyl, CycA, etc.; AA 1 is a single bond, amino acid residue, etc.; AA 2 is a single bond, amino acid residue, etc.; R 7 and R 8 are hydrogen, alkyl, etc.; R 9 is hydrogen, alkyl, etc., and a non-toxic salt thereof. The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of inflammatory diseases, diseases induced by apoptosis, diseases induced by disorders of immune responses, autoimmune diseases, diseases induced by decomposition of proteins which compose organism, shock, circulatory system disorders, blood coagulation systems disorders, malignant tumors, acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC), parasitic diseases, nerve degeneration diseases, pulmonary disorders, bone resorption diseases, endocrinesthenia, etc.

  公式（I）的1,3,4-噁二唑啉衍生物，其中W为氧、硫；R为氢、烷基、环烷A等；AA1为单键、氨基酸残基等；AA2为单键、氨基酸残基等；R7和R8为氢、烷基等；R9为氢、烷基等，以及其非毒性盐。 公式（I）的化合物对半胱氨酸蛋白酶具有抑制活性，因此可用作预防和/或治疗炎症性疾病、凋亡诱导的疾病、免疫反应紊乱引起的疾病、自身免疫疾病、由组成生物体的蛋白质分解引起的疾病、休克、循环系统紊乱、血液凝固系统紊乱、恶性肿瘤、获得性免疫缺陷综合症（AIDS）和AIDS相关综合症（ARC）、寄生虫病、神经退行性疾病、肺部疾病、骨吸收疾病、内分泌亢进等方面具有用途。
• Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
  申请人：——

  公开号：US20040204368A1

  公开（公告）日：2004-10-14

  An oxadiazole derivative of formula (I) and a non-toxic salt thereof, 1 wherein all symbols have the same meaning as described in the specification. The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of inflammatory diseases, diseases induced by apoptosis, diseases induced by disorders of immune responses, autoimmune diseases, diseases induced by decomposition of proteins which compose organism, shock, circulatory system disorders, blood coagulation system(s) disorders, malignant tumors, acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC), parasitic diseases, nerve degeneration diseases, pulmonary disorders, bone resorption diseases, endocrinesthenia, etc.

  公式（I）的一种噁二唑衍生物及其非毒性盐， 其中所有符号的含义与规范中描述的相同。公式（I）的化合物具有对半胱氨酸蛋白酶的抑制活性，因此它可用作预防和/或治疗炎症性疾病、由细胞凋亡引起的疾病、由免疫反应紊乱引起的疾病、自身免疫疾病、由构成生物体的蛋白质分解引起的疾病、休克、循环系统紊乱、血液凝固系统紊乱、恶性肿瘤、获得性免疫缺陷综合症（AIDS）和AIDS相关综合症（ARC）、寄生虫病、神经退行性疾病、肺部疾病、骨吸收疾病、内分泌亢进等方面的药剂。
• RESIST COMPOSITION AND METHOD FOR FORMING RESIST PATTERN
  申请人：TOKYO OHKA KOGYO CO., LTD.

  公开号：US20170371241A1

  公开（公告）日：2017-12-28

  A resist composition containing a resin component having a structural unit represented by general formula (a0-1), and a compound represented by general formula (b1). In general formula (a0-1), R is a hydrogen atom, an alkyl group, or a halogenated alkyl group. Va 1 is a divalent hydrocarbon group. n a1 represents an integer of 0 to 2. Ra′ 12 and Ra′ 13 are a monovalent chain saturated hydrocarbon group having 1 to 10 carbon atoms or a hydrogen atom. Ra′ 14 is a phenyl group, a naphthyl group, or an anthryl group. In general formula (b1), R b1 represents a cyclic hydrocarbon group. Y b1 represents a divalent linking group containing an ester bond. V b1 represents an alkylene group, a fluorinated alkylene group, or a single bond. m is an integer of 1 or more, and M m+ is an m-valent organic cation.

  一种电阻组分，包含具有一般式（a0-1）所代表的结构单元的树脂组分，以及一种由一般式（b1）所代表的化合物。在一般式（a0-1）中，R是氢原子、烷基或卤代烷基。Va1是双价碳氢基团。na1表示0至2的整数。Ra′12和Ra′13是具有1至10个碳原子的单价链饱和碳氢基团或氢原子。Ra′14是苯基、萘基或蒽基。在一般式（b1）中，Rb1代表环烃基。Yb1代表含有酯键的双价连接基团。Vb1代表烷基、氟化烷基或单键。m是1或更多的整数，Mm+是m价有机阳离子。

表征谱图